Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC) (AUTENTIC)
Prediction of Immune-related Adverse Events Induced by Anti-CTLA4 and Anti-PD1/PDL1 Drugs by Means of a Battery of Autoantibodies. a Multicenter Prospective Observational Cohort Study
Sponsor: Complejo Hospitalario de Navarra
Listed as NCT03868046, this observational or N/A phase trial focuses on Cancer and Metastatic Cancer and remains completed. Sponsored by Complejo Hospitalario de Navarra, it has been updated 13 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
May 2025 — Sep 2025 [monthly]
Completed
Status: Unknown → Completed
-
Mar 2025 — May 2025 [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Apr 2023 — Jul 2024 [monthly]
Recruiting
-
Dec 2021 — Apr 2023 [monthly]
Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2019 — Nov 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting
-
Apr 2019 — Sep 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Complejo Hospitalario de Navarra
- Hospital Donostia
- Hospital Galdakao-Usansolo
- Hospital Universitario Araba
- Hospital de Basurto
For direct contact, visit the study record on ClinicalTrials.gov .